When Traditional Antidepressants Stop Working: What Comes Next

Most patients who come to me for ketamine have been on medication number four, five, or six. They are not treatment-naive. They have tried the reasonable things in the reasonable order, and the reasonable things have stopped being enough.

I want to describe that pattern clearly, because the moment you realize the medication shuffle is not going to solve your depression is usually the moment you start looking for something else. Recognizing that moment sooner is worth something.

The Shuffle

The pattern is usually some version of this. An SSRI first, Lexapro or Zoloft. Six months. A little help with anxiety, motivation flattened, emotional range narrowed. The physician swaps to Wellbutrin. Energy returns but the anxiety roars back. A switch to Prozac, six months more, and a kind of emotional flatness that the patient finds harder to describe than the original depression. Effexor after that, with the first real taste of what missing a dose feels like. Cymbalta brings weight gain and sexual side effects. And then somebody suggests Zoloft, which was the first one, and that is the moment the patient notices: we are guessing now.

Two weeks of side effects with no benefit. By week six, maybe it is working. By week twelve, plateau or a new problem. By month six, let us try something else. The patient is playing whack-a-mole with their own brain chemistry, and the moles keep winning.

What "Not Working" Actually Means

The inflection point is rarely dramatic. Most patients do not hit it on a bad day. They hit it on a decent day, the kind where medication is holding baseline well enough that they can notice the ceiling.

A decent day on antidepressant number five looks like this: basic tasks are manageable. Work meetings do not trigger panic. Sleep is okay with pharmaceutical help. Nobody is in crisis. And nobody is really living either. Joy is absent. Curiosity is absent. Plans more than a week out feel abstract. The person functions. That is what the medication has given them. For some patients that is enough and I do not argue with it. For many, it is not.

The question to ask yourself, sitting in the car after therapy, is is this really as good as it gets? If the answer is no, the next question is what to do about it.

Treatment-Resistant Depression Is Not a Failure of Effort

Thirty to forty percent of people with depression do not respond adequately to first-line treatments. There is a name for it: treatment-resistant depression, or TRD. We have a longer piece on understanding treatment-resistant depression and on why ketamine works when two or more antidepressants have failed if you want the clinical detail.

The thing that changes for most patients when they hear this is not the diagnosis. It is the reframe. SSRIs and SNRIs target the serotonin and norepinephrine pathways. Those are not the only circuits involved in depression; they are the ones we happen to have good drugs for. If your depression is mediated more by glutamate dysregulation, HPA-axis dysfunction, or neuroplasticity deficits, serotonin modulation is going to underperform no matter how many SSRIs you cycle through. Different pathway, different tool.

This is a medical reality, not a character failure. It is useful to name that out loud.

Why Ketamine Is on the Short List

Ketamine is on the short list for TRD because it works through a mechanism antidepressants do not. It modulates glutamate at the NMDA receptor and drives BDNF expression, which opens a window of heightened neuroplasticity. Patients who have responded to nothing else often respond to this. The S-enantiomer, esketamine, is FDA-approved as Spravato nasal spray for TRD. The racemic form used in at-home sublingual programs is prescribed off-label by physicians.

The other options on the short list are TMS (transcranial magnetic stimulation), ECT (electroconvulsive therapy in severe cases), and the newer psychedelic-assisted protocols that remain largely in trial settings. MAOIs are still around and still underused. Medication augmentation with lithium or atypical antipsychotics is the traditional escalation path and works for some patients.

Ketamine's advantage in this set is speed of onset (hours to days rather than weeks) and a tolerability profile that, handled correctly, beats most of the alternatives on quality of life.

What Changes With Ketamine (And What Does Not)

Ketamine does not cure depression. Nothing cures depression. What it does, for most responders, is break the groove the brain has been stuck in, long enough and widely enough for other work to take hold. Patients tell me the difference shows up in small things: bad days feel temporary again instead of permanent, creative projects sound interesting, relationships feel like connection rather than obligation, plans extend further out than next week.

It does not do this on its own. The neuroplasticity window ketamine opens is an opportunity, not an outcome. Patients who combine ketamine with psychotherapy, sleep protection, some form of movement, and real integration practice do substantially better than patients who treat sessions as isolated drug events. I say this often because it is true often.

For Patients on Medication Number Four or Five

If this is where you are, a few things worth knowing.

Ask your psychiatrist directly about treatment-resistant depression. Many will not raise the topic unless prompted. The conversation is worth initiating.

The newer options are more accessible than they were two years ago. Ketamine, TMS, and the emerging psychedelic protocols have moved from academic centers into practice. You do not necessarily need a referral to a specialty clinic.

At-home ketamine programs exist, including ours, with proper medical oversight. They fit lives that cannot accommodate twice-weekly clinic visits, and for stable medical candidates the outcomes are comparable to in-clinic IV. We have a comparison at at-home ketamine vs. infusion clinics.

You are not broken. Your brain may need a different tool. Being honest about what is not working is usually the beginning of finding what will.

If traditional antidepressants have not given you the relief you need, ketamine therapy may be worth exploring.

Check your eligibility today →

Frequently Asked Questions

How do I know when antidepressants have stopped working for me?

The clinical definition is failure to achieve adequate response (typically 50% reduction in depression severity scores) after two or more trials of different antidepressants at adequate doses for adequate durations (six to eight weeks each). The lived definition is usually clearer: you're stable but not well, you're functioning but not living, and you suspect this is as good as the medications are going to get. If you've been on antidepressants for more than a year and you'd describe yourself as "better than untreated but still not well," you're likely meeting TRD criteria.

Should I keep trying more antidepressants before considering ketamine?

Maybe one more, depending on what you've already tried. After two failed trials, the remission rates for trial number three or four drop to roughly 14% and 13% respectively (per STAR*D). Cycling endlessly through SSRIs and SNRIs that target the same neurotransmitter system rarely produces a different outcome. After two failed trials at adequate doses and durations, the case for trying a different mechanism (ketamine, TMS, ECT, or augmentation) is generally stronger than another standard antidepressant.

What's the difference between regular depression and treatment-resistant depression?

Mild-to-moderate depression usually responds to first-line treatment (an SSRI plus therapy), and the response is durable. TRD is depression that has not responded adequately to two or more standard medication trials despite appropriate dose and duration. Severity at presentation isn't the distinguishing feature; many TRD patients started with what looked like mild-to-moderate depression and progressed because the standard tools didn't work. About 30 percent of patients with depression eventually meet TRD criteria.

How long should I wait before changing antidepressants?

Six to eight weeks at a therapeutic dose is the standard adequate-trial definition. Earlier than that, you're likely seeing side effects without full benefit, which can produce false-negative judgments. Longer than that without meaningful response (a 50% reduction in depression scores) and the trial has effectively failed. One nuance: partial response at six weeks sometimes converts to full response by week ten or twelve, so a moderate-but-inadequate response may justify extending the trial. No response at all by week six is a clearer signal to switch.

Are TMS, ECT, or ketamine actually accessible without a referral to a major academic center?

Yes, much more than they were two years ago. Spravato (esketamine) is FDA-approved for TRD and increasingly available through community psychiatric clinics. TMS clinics have proliferated and are covered by most insurance with prior authorization. At-home ketamine programs (including ours) operate under physician supervision via telehealth. ECT remains the most centralized of these (still typically delivered in hospital outpatient settings), but the others are now accessible from most US zip codes.

Why does ketamine work when SSRIs don't?

Different mechanism. SSRIs work by increasing serotonin availability at the synapse; the effect builds slowly over weeks. Ketamine works through the glutamate system at NMDA receptors, triggers BDNF release, and produces synaptogenesis (new synaptic connections) within hours. About 30 to 40 percent of TRD patients are non-responders to all serotonin-targeting medications because their depression isn't primarily serotonergically mediated. For those patients, ketamine's different target produces results that no number of additional SSRI trials would.

What does it mean when my psychiatrist suggests "augmentation"?

Augmentation is adding a second medication to an existing antidepressant rather than switching. Common augmentation strategies include lithium (the most evidence-supported augmentation for TRD, though under-used), atypical antipsychotics (aripiprazole, quetiapine), thyroid hormone (T3), and stimulants. Augmentation can produce response in some patients who haven't responded to monotherapy, but it adds side effects and doesn't address the underlying mechanism question.

Should I taper off my current antidepressant before trying ketamine?

Generally no. Most clinical trials of ketamine for TRD explicitly allow patients to continue their existing antidepressants, and the combination is often more effective than ketamine alone (the SSRI provides a stable floor while ketamine drives the rewiring). The exceptions are MAOIs, which require a 14-day washout, and high-dose tramadol or other clearly serotonergic agents. See our deep-dive on combining ketamine with SSRIs.

References

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PubMed: 17074942 The STARD study is the source for the "30 to 40 percent non-responder" figure and the diminishing-returns pattern across successive medication trials referenced throughout the body.*

2. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. PubMed: 16894061 Foundational NIMH trial establishing ketamine's rapid antidepressant effect in TRD via NMDA antagonism. The mechanistic basis for the glutamate / BDNF / neuroplasticity story.

3. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893-903. PubMed: 31166571 Established Spravato (esketamine) as FDA-approved for TRD as add-on to an oral antidepressant. The basis for "FDA-approved as Spravato nasal spray for TRD" in the body.

4. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. PubMed: 23982301 Two-site RCT showing 64% response rate in TRD patients at 24 hours after a single ketamine infusion vs 28% with midazolam. Supports the claim that ketamine succeeds where multiple SSRI trials have failed.